Pharma Pulse: Ipsen’s Global Tazemetostat Withdrawal and FDA Approval of Deucravacitinib for Psoriatic Arthritis

Mar 10, 12:00 PM
Headliner
Share
Subscribe
In today's Pharma Pulse, Ipsen voluntarily withdraws tazemetostat due to safety signals, while the FDA approves deucravacitinib for active psoriatic
arthritis.

Share
Subscribe
Next
Pharma Pulse: FDA Approval of Leucovorin Calcium for CFD and Persistent Inequities in OTC Naloxone Access
Top episodes
Overcoming Supply Chain Challenges
by Pharma Pulse
Incorporating AI into Commercialization Plans
by Pharma Pulse
The Capabilities of a 3PL Provider
by Pharma Pulse